Introduction
Inflammatory bowel disease (IBD) shares many features with other chronic inflammatory diseases (CIDs), such as rheumatoid arthritis and psoriasis, which are characterized by dysregulated immune responses and systemic manifestations. While IBD is primarily associated with inflammation in the gut, it can also lead to extra-intestinal symptoms, including joint pain and skin lesions, which are commonly observed in these other diseases. Understanding commonalities and differences among these chronic inflammatory conditions is important for developing more effective therapies that can target the underlying immune dysregulation and improve patients' overall quality of life.
Aims & Methods
We aim to identify both the common disease signatures shared between IBD and other CIDs, as well as the disease-specific signatures unique to each condition. A cross-sectional cohort of 650 patients with CIDs, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, psoriasis, and systemic lupus erythematosus (SLE), were recruited from the University Hospital Kiel. Peripheral blood samples were collected from this cohort, along with samples from 202 healthy controls, and subjected to RNA sequencing and methylation profiling. At the time of sample collection, the patients in the cohort underwent detailed clinical phenotyping including assessments of disease activity and symptoms. Additionally, these patients were followed up for up to 5 years to record any potential future complications that may arise.
Results
We performed differential expression and methylation analysis between each CID diagnosis and the healthy control group to identify shared molecular signatures. Our analysis showed that IBD shared the most differential signatures with rheumatoid arthritis, indicating common pathways in their pathogenesis. Psoriatic diseases also shared a significant proportion of differentially expressed and methylated patterns, while SLE had the least in common with other CIDs, suggesting distinct molecular pathways driving its pathogenesis. Interestingly, we were able to identify core transcriptomic changes that persisted even during inactive disease by separating the analysis by disease activity. These signatures were shared across different CIDs and were correlated with DNA methylation changes, reflecting the molecular mechanism of chronicity. Commonly upregulated genes across all CIDs were enriched in pathways related to inflammatory response, cytokine signaling, neutrophil chemotaxis, and humoral immune response. Disease-specific pathways included interferon-beta production in SLE, several metabolic processes in psoriasis, and complement activation in ulcerative colitis. Disease-specific methylation signatures were mainly located in CpG islands, while methylation signatures in enhancers were shared among most diseases. Our large cohort design enabled us to identify subgroup of patients across CIDs that share molecular characteristics, including a cluster of genes related to interleukin and interferon signaling upregulated in 71 samples belonging to different CIDs.
Conclusion
In conclusion, our study identified common and disease-specific molecular signatures in CIDs. Our findings suggest shared immune dysregulation pathways underlying the pathogenesis of IBD and rheumatoid arthritis, as well as potential commonalities between psoriatic diseases. We show the clear presence of core signatures of disease regardless of disease activity, which could represent insights into actionable targets for causative treatments and better disease control of CIDs.